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hypoxic pulmonary vasoconstriction; heme oxygenase ARTERIAL VESSELS generate carbon monoxide (CO) along with biliverdin via metabolism of heme by heme oxygenase (HO) isoforms -1 and -2 (36) . Arterial vessels express HO-2 constitutively, whereas HO-1 is primarily expressed as the result of exposure to inducing factors or conditions (24, 30) . Products of heme metabolism by HO possess biological activities that influence vascular functions. Biliverdin and its metabolic product bilirubin are antioxidants capable of preventing oxidantinduced microvascular leukocyte adhesion (6) . CO stimulates soluble guanylate cyclase (19) and Ca 2ϩ -activated K ϩ (K Ca ) channels (10, 30) in vascular smooth muscle, interferes with the expression and release of endothelin-1 (ET-1) in endothelial cells (18) , and inhibits endothelial nitric oxide synthase (27) . CO of vascular origin attenuates vasoconstrictor responsiveness to myogenic stimuli in rat gracilis muscle arterioles (37) and to constrictor agonists in the rat renal interlobar arteries (10) , the rat tail artery (30) , and aorta (3) . CO of vascular origin was also implicated in the mediation of dilatory responses to acetylcholine in porcine pulmonary arteries (35) , to heme-L-lysinate in small rat mesenteric arteries (22) , and to acute hypoxia in cerebral arteries of piglets (15) .
Hypoxia causes constriction of pulmonary arterial vessels in vitro and in vivo (9, 14, 23, 38) . The pulmonary vasoconstriction elicited by hypoxic conditions is attenuated by blockade of ET-1 subtype A (ET A ) receptors, suggesting contribution of ET-1 to the mechanism underlying the constrictor response (9, 23) . That HO-derived CO downregulates ET-1 expression and release in endothelial cells (18) raises the possibility that CO inhibits the ET-1-dependent component of the constrictor response to hypoxia in pulmonary vessels. However, the result of studies examining modulation of hypoxia-induced pulmonary vasoconstriction by CO is less than conclusive. Although exogenous CO dilates pulmonary vessels preconstricted with an agonist of thromboxane receptors (21) , exogenous CO does not consistently elicit pulmonary vasodilation during hypoxic conditions (1, 28) . While experimental interventions that enhance lung HO-1 expression prevent the pulmonary hypertension produced by chronic hypoxia in rats (4), the elevation of pulmonary arterial pressure produced by chronic hypoxia was similar in HO-1 null mice and the corresponding wild-type controls (33) . In addition, the inhibitors of HO affect hypoxiainduced pulmonary vasoconstriction inconsistently, having little or no effect under basal conditions, while intensifying the response when nitric oxide synthesis is decreased (2) .
The present study was designed to test the hypothesis that CO produced by pulmonary arterial vessels attenuates hypoxiainduced pulmonary vasoconstriction by interfering with the vascular formation or actions of ET-1. We conducted experiments in the small pulmonary arteries of rats for the following reasons: 1) to quantify the generation of CO and determine whether it is affected by acute hypoxia, 2) to examine the effect of interventions that decrease HO activity or expression on the vascular response to acute hypoxia, and 3) to determine the effect of HO inhibition on constrictor responsiveness to ET-1 and vascular ET-1 levels.
MATERIALS AND METHODS
Chemicals. Chromium mesoporphyrin (CrMP) was purchased from Porphyrin Products (Logan, UT), and stock solutions were prepared in 50 mmol/l Na 2CO3. CO was purchased from Tech Air (White Plains, NY), and CO-saturated solution (1 mmol/l) was prepared immediately before use (37) . ET-1 was purchased from Bachem Bioscience (King of Prussia, PA). L-754142 was a gift from Merck Research Laboratories (Rahway, NJ). Antisense (AS) oligodeoxynucleotides (ODN) complementary to rat HO-1 mRNA (HO-1 AS-ODN) and rat HO-2 mRNA (HO-2 AS-ODN) and the corresponding scrambled (S) ODN (HO-1 S-ODN and HO-2 S-ODN) were synthesized by Genosys Biotechnologies (Woodland, TX); each ODN was phosphorothioated on the first three bases of the 3Ј end and was purified by high-pressure liquid chromatography. The sequence of HO-1 AS-ODN is 5Ј-GGCGCTC-CATCGCGGGACTG-3Ј and target bases ϩ10 to Ϫ9 of HO-1 mRNA; the sequence of HO-2 AS-ODN is 5Ј-TCTGAAGACATT-GTTGCTGA-3Ј and targets bases ϩ11 to Ϫ9 of HO-2 mRNA. The sequence of HO-1 S-ODN is 5Ј-TCCAGCGGCGTCAGCGGTGC-3Ј, and the sequence of HO-2 S-ODN is 5Ј-GATCTGACTTCAAGT-GATTG-3Ј. The effectiveness of HO-1 AS-ODN and HO-2 AS-ODN to reduce tissue expression of HO-1 and HO-2, respectively, was documented previously (5, 10) .
Animals. Experiments were conducted on male Sprague-Dawley rats (200-300 g; Charles River; Wilmington, MA) according to protocols approved by the Institutional Animal Care and Use Committee. In the experiments using isolated pulmonary vessels, the animals were anesthetized (60 mg/kg ip pentobarbital sodium), heparin (1,000 U/kg) was injected intravenously, and the lungs were removed. Immediately thereafter, the lungs were placed on a dish filled with ice-cold Krebs buffer composed of (in mmol/l) 118.5 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 25.0 NaHCO3, and 11.1 dextrose, and pulmonary intralobar arteries (100-200 m of internal diameter) were dissected out for use in vascular contractility studies and for assessment of HO isoform expression, CO production, and ET-1 levels. In some experiments, the animals were treated 24 h before experimentation with HO-1 AS-ODN, HO-2 AS-ODN, HO-1 S-ODN, or HO-2 S-ODN. The ODN were encapsulated in liposomes (1:1 molar ratio nucleotide/lipid) prepared using premixed 1,2-bis-(oleoyloxy)-3-(trimethylammonio)propane and L-a-dioleoyl phosphatidylethanolamine. The cationic lipid mixture and instructions for preparation of the lipid/oligomer complex were supplied by Avanti Polar Lipids (Alabaster, AL). Liposomes containing HO-1 AS-ODN, HO-2 AS-ODN, HO-1 S-ODN, or HO-2 S-ODN were suspended in 5% dextrose and injected (2 mg/kg) intravenously.
In studies examining the effect of hypoxia on pulmonary artery pressure (7), rats were anesthetized with Inactin (100 mg/kg ip), and cannulas were placed in the trachea, a femoral vein for drug administration, and in the pulmonary artery (via the right jugular vein and the right ventricle) for measurement and recording of pressure by means of a pressure transducer (model P23 ID, Statham Division, Gould; Oxnard, CA) coupled to a polygraph (model 7D, Grass Instruments; Quincy, MA).
Expression of HO-1 and HO-2 isoforms. HO-1 and HO-2 protein expression was assessed in isolated pulmonary intralobar arteries of rats treated 24 h earlier with HO-1 AS-ODN, HO-2 AS-ODN, HO-1 S-ODN, or HO-2 S-ODN. The tissues were homogenized, the homogenate was centrifuged at 10,000 g, and the supernatant was analyzed for HO-1 and HO-2 by immunoblotting as previously described (10) . ␤-Actin was also assayed, the results taken as an index of the adequacy of sample loading.
Assessment of CO release from pulmonary arteries ex vivo. Segments of pulmonary intralobar arteries (ϳ4 segments 2 mm in length) were placed into amber glass vials (2 ml) containing 1.0 ml of Krebs buffer gassed with 95% O2-5% CO2 (PO2, 160 mmHg), or when so indicated 95% N 2-5% CO2 (PO2, 15 mmHg). The vials were capped tightly with rubberized Teflon liners, and the samples were incubated for 60 min at 37°C. In a limited number of experiments, the HO inhibitor CrMP (15 mol/l) was included in the buffer. The incubations were terminated by placement of the vials on ice. Subsequently, internal standards made of isotopically labeled CO ( 13 C 16 O and 13 C 18 O) were injected into samples and the CO content of the headspace gas was determined by gas chromatography/mass spectroscopy, as previously described (10, 37).
Assessment of vascular ET-1 levels.
Segments of pulmonary intralobar arteries were placed inside glass vials containing Krebs buffer (1 ml) gassed with 95% O 2-5% CO2 or 95% N2-5% CO2, the vials were capped, and the samples were incubated for 60 min at 37°C. When so noted, the incubations were conducted in buffer containing CrMP (15 mol/l). At the conclusion of the incubation, the tissues were homogenized in 1 mol/l HCl containing 1% acetic acid, 1% trifluoroacetic acid, and 1% NaCl, and the resulting sample was processed (12) and assayed for ET-1 by radioimmunoassay using a commercially available kit (Peninsula Laboratories; San Carlos, CA).
Effect of hypoxia on isometric tension development in pulmonary intralobar arteries. Pulmonary arterial vessels with an internal diameter averaging 153 Ϯ 12 m were cut into ring segments 2 mm in length. The vascular rings were mounted on 25 m stainless steel wires in the chambers of a multivessel myograph (J.P. Trading; Aarhus, Denmark) for measurement of isometric tension (38) . The vessels were bathed in Krebs buffer maintained at 37°C and gassed with 95% O 2-5% CO2, unless indicated otherwise. After an equilibration period (30 min), the vessels were stretched radially so that the internal circumference was equivalent to 90% of the vessel's normal size if relaxed under a transmural pressure of 17.5 mmHg (20), which approximates the mean pressure measured in the pulmonary artery of rats under normoxic conditions. Isometric tension was monitored continuously and was expressed as milliNewtons per millimeter of vessel length.
Experiments were initiated by exposing the vessels to Krebs buffer modified by increasing the concentration of KCl to 80 mmol/l (by equimolar exchange with NaCl) to ascertain reproducibility of contractile responses. Subsequently, the vessels were washed with unmodified Krebs buffer and allowed to rest for 30 min before hypoxic conditions were established by gassing the bathing buffer with 95% N2-5% CO2 and assessment of ensuing changes in isometric tension. The effect of hypoxia on isometric tension was investigated in pulmonary intralobar arteries taken from rats treated 24 h before experimentation with HO-1 AS-ODN, HO-2 AS-ODN, or the corresponding HO-1 S-ODN or HO-2 S-ODN. The effect of hypoxia also was examined in endothelium-intact and endothelium-denuded (38) pulmonary vessels from untreated normal rats, bathed in buffer containing and not containing the HO inhibitor CrMP (15 mol/l). In these experiments, the effectiveness of the denudation procedure was ascertained by documenting that acetylcholine (10 mol/l)-induced relaxation of denuded pulmonary vessels precontracted with PGF2␣ (10 mol/l) was minimal (Ͻ10% of PGF2␣-induced tone) relative to the response in endothelium intact vessels (Ͼ50% of PGF2␣-induced tone). Additional studies (32) , conducted in preparations bathed in buffer containing CrMP (15 mol/l), compared the vascular response to hypoxia in vessels exposed and not exposed to exogenous CO (1-100 mol/l), biliverdin (10 mol/l), or to L-754142 (10 mol/l), a nonselective antagonist of ET-1 receptors. The pulmonary vascular response to acute hypoxia in preparations treated and not treated with CrMP (15 mol/l) was also examined after inclusion of 1.0 mol/l PGF2␣ into the buffer, which elicited a modest elevation of isometric tension (from 0.36 Ϯ 0.09 to 0.44 Ϯ 0.09, n ϭ 12; P Ͻ 0.05) believed to be a priming factor for expression of hypoxia-induced contraction of pulmonary arterial smooth muscle ex vivo (14) .
Effect of HO inhibition of vascular responsiveness to ET-1. Ring segments of pulmonary intralobar arteries from normal rats were prepared for measurement of isometric tension. Concentration-response curves to ET-1 (10 Ϫ12 Ϫ 5 ϫ 10 Ϫ7 mol/l) were constructed by increasing cumulatively the concentration of agonist every 3 min and recording the resulting changes in tension at the end of the 3-min period. The experiments were conducted in vessels bathed in buffer containing and not containing CrMP (15 mol/l); contractile responses to ET-1 in CrMP-treated preparation also were examined after the addition of exogenous CO (1.0 mol/l) to the buffer.
Effect of acute hypoxia on pulmonary artery pressure. Pulmonary artery pressure was monitored in instrumented rats during successive periods of ventilation with air and a hypoxic gas mixture (5% O2-5% CO2-90% N2). The effect of hypoxia also was examined after pretreatment with the HO inhibitor CrMP (40 mol/kg iv) or with both CrMP and the nonselective antagonist of ET-1 receptors L-745142 (15 mg/kg iv).
Data analysis. Data are expressed as means Ϯ SE. The concentration-response data derived from each vessel were fitted separately to a logistic function by nonlinear regression and the maximum asymptote of the curve (R max), and the concentration of ET-1 producing EC50 data was calculated with the use of commercially available software (Prism 2.01; GraphPad Software for Science; San Diego, CA). Data on vascular responsiveness to hypoxia and ET-1 in different groups of vessels were compared by ANOVA, followed by the Newman-Keuls post hoc analysis to make specific comparisons. Student's t-test was used to compare data on CO release and tissue ET-1 levels. The null hypothesis was rejected at P Ͻ 0.05.
RESULTS
HO expression and CO production in pulmonary arterial vessels. Proteins with the molecular mass of HO-1 and HO-2 were identified by immunoblotting in homogenates of pulmonary intralobar arteries (Fig. 1) . The expression of HO-1 protein in pulmonary vessels was less intense (P Ͻ 0.05) in rats treated with HO-1 AS-ODN than in rats treated with HO-1 S-ODN (Fig. 1) . The expression of HO-2 protein in vessels of rats treated with HO-2 AS-ODN was less intense (P Ͻ 0.05) than in vessels of rats treated with HO-2 S-ODN (Fig. 1) .
Pulmonary intralobar arteries released CO into the headspace during incubation in Krebs buffer for 60 min (Fig. 2) . CO release was virtually identical in vessels taken from rats treated with HO-1 S-ODN and HO-1 AS-ODN but was decreased (P Ͻ 0.05) in vessels from animals treated with HO-2 AS-ODN relative to the release from vessels of rats treated with HO-2 S-ODN. CO release from vessels bathed in media containing the HO inhibitor CrMP also was diminished (P Ͻ 0.05). CO release from vessels bathed in media gassed with 95% O 2 -5% CO 2 (280 Ϯ 44 pmol/l) was comparable to the release from vessels bathed in media gassed with 95% N 2 -5% CO 2 (287 Ϯ 70 pmol/l). opment of isometric tension in vessels taken from rats treated with either HO-1 S-ODN or HO-2 S-ODN. Figure 4 illustrates the effect of acute hypoxia on isometric tension development in endothelium-intact and -denuded pulmonary artery rings bathed in buffer with and without CrMP (15 mol/l). KC1 at 80 mmol/l produced comparable increase of isometric tension in endothelium-intact and endotheliumdenuded pulmonary intralobar artery rings (1.04 Ϯ 0.06 vs. 1.06 Ϯ 0.17 mN/mm). Basal isometric tension did not differ significantly among the groups before hypoxia. Hypoxia did not stimulate tension development in vessels not exposed to CrMP, regardless of whether the preparation was denuded of endothelium or not. In contrast, hypoxia promoted tension development in endothelium-intact preparations exposed to the HO inhibitor CrMP (15 mol/l). Hypoxia also induced contraction of endothelium-denuded preparations after CrMP treatment, but the response was greatly attenuated (P Ͻ 0.05) relative to that in rings with endothelium. The inclusion of exogenous CO (1-100 mol/l) into the bathing buffer caused concentration-dependent attenuation (P Ͻ 0.05) of the constrictor response to hypoxia in endothelium-intact vessels treated with CrMP (Fig. 5) . In contrast, the inclusion of biliverdin (10 mol/l) did not reduce hypoxia-induced pulmonary vascular contraction.
Effect of interventions that decrease HO expression and/or
Pulmonary intralobar artery rings bathed in Krebs buffer containing PGF 2␣ (1 mol/l) developed isometric tension during hypoxia both in the absence (from 0.39 Ϯ 0.19 to 1.09 Ϯ 0.24 mN/mm; P Ͻ 0.05; n ϭ 4) and the presence of CrMP (from 0.52 Ϯ 0.16 to 2.43 Ϯ 0.60 mN/mm; P Ͻ 0.05; n ϭ 4). Hypoxia-induced vascular contraction in preparations pretreated with CrMP was more intense than in preparations not pretreated (1.91 Ϯ 0.51 vs. 0.70 Ϯ 0.19 mN/mm; P Ͻ 0.05); exogenous CO (1 mol/l) attenuated (0.71 Ϯ 0.15 mN/mm; P Ͻ 0.05, n ϭ 4) hypoxia-induced vascular contraction in vessels pretreated with CrMP.
ET-1 and hypoxia-induced pulmonary vascular contraction. The tension development induced by acute hypoxia in rings of pulmonary intralobar arteries exposed to CrMP was greatly attenuated by the addition of the ET-1 receptor antagonist L-754142 (10 mol/l) to the bathing buffer (Fig. 6) . Figure 7 illustrates the effect of ET-1 on tension development in rings of pulmonary intralobar arteries bathed in buffer not containing and containing the HO inhibitor CrMP (15 mol/l), alone and with CO (1 mol/l). ET-1 elicited concentration-dependent tension development in all the groups. Exposure of the vessels to CrMP caused a leftward shift in the concentration-response curve to the constrictor peptide, decreasing the EC 50 but not the R max . The sensitization caused by ex vivo treatment with CrMP was offset by exogenous CO, which caused a rightward displacement of the concentrationresponse curve to ET-1 and increased the EC 50 without altering the R max . Figure 8 depicts data on ET-1 levels in pulmonary intralobar arteries incubated for 60 min in Krebs buffer gassed with 95% O 2 -5% CO 2 or with 95% N 2 -5% CO 2 , both in the presence and absence of CrMP. ET-1 levels were comparable in vessels incubated during hypoxic and nonhypoxic conditions in the absence of CrMP. CrMP increased (P Ͻ 0.05) the vascular level of ET-1 both in nonhypoxic and hypoxic preparations. ET-1 levels were higher (P Ͻ 0.05) in hypoxic vessel treated with CrMP than in nonhypoxic preparations treated with the HO inhibitor. Also shown in Fig. 8 , pulmonary intralobar arteries taken from rats treated with HO-2 S-ODN displayed similar levels of ET-1 when incubated under hypoxic and nonhypoxic conditions. In contrast, pulmonary vessels taken from rats treated with HO-2 AS-ODN displayed higher (P Ͻ 0.05) levels of ET-1 when incubated under hypoxic than nonhypoxic conditions. Relative to data in pulmonary arteries from rats treated with HO-2 S-ODN, pulmonary arteries from rats treated with HO-2 AS-ODN had higher (P Ͻ 0.05) levels of ET-1 both during incubation under nonhypoxic and hypoxic conditions. Fig. 9 , pulmonary artery pressure increased (P Ͻ 0.05) acutely by 3.1 Ϯ 0.1 mmHg in rats breathing a hypoxic gas mixture (5% O 2 -5% CO 2 -90% N 2 ) over a 2-min period. Acute hypoxia elicited an even greater (P Ͻ 0.05) elevation of pulmonary arterial pressure after pretreatment of rats with CrMP (40 mol/kg iv; 7.5 Ϯ 0.7 mmHg). However, acute hypoxia did not increase pulmonary artery pressure in rats after pretreatment with both CrMP and the nonselective ET-1 receptor antagonist L745142 (15 mg/kg iv).
Effect of interventions that inhibit HO and block ET-1 receptors on changes in pulmonary artery pressure produced by acute hypoxia. As illustrated in

DISCUSSION
This study shows that rat pulmonary intralobar arteries express both HO-1 and HO-2 proteins, which is consistent with previous observations (17, 35) in pulmonary arteries of other animal species, and that the expression of HO-1 and HO-2 is depressed in vessels taken from rats treated with HO-1 AS-ODN and HO-2 AS-ODN, respectively. The study also demonstrates that rat pulmonary intralobar arteries incubated in Krebs buffer release CO into the headspace gas. CO release from these vessels is largely HO dependent because it was decreased to ϳ30% of the control value by CrMP, a metalloporphyrin, which inhibits both HO-1 and HO-2 (29) . That CO release from pulmonary intralobar arteries of rats treated with HO-2 AS-ODN, but not with HO-1 AS-ODN, is exceeded by 8 . Assessment of ET-1 levels in rat pulmonary intralobar arteries incubated (60 min at 37°C) in media gassed with 95% O2-5% CO2 or 95% N2-5% CO2. The arteries were obtained from untreated rats and from rats treated with HO-2 S-ODN or HO-2 AS-ODN (B). Pulmonary intralobar arteries from untreated rats were incubated in the absence and presence of CrMP (A; 15 mol/l). The results are means Ϯ SE. n, Number of experiments. *P Ͻ 0.05, relative to control data in vessels not exposed to CrMP. †P Ͻ 0.05, relative to corresponding data in vessels bathed in oxygenated media.
that from vessels of animals treated with the corresponding scrambled antisense oligodeoxynucleotides implies that HO-2, rather than HO-1, is linked to CO release under the conditions of our study. HO-2-dependent formation of CO was documented previously in rat renal interlobar arteries and gracilis muscle arterioles (10, 37) .
The major finding of our studies on isometric tension development, in isolated rat pulmonary intralobar arteries, is that acute hypoxia elicits contraction of vessels pretreated with CrMP to inhibit HO isoforms, and of vessels taken from rats pretreated with HO-2 AS-ODN to decrease HO-2 expression, but not of untreated vessels or of vessels obtained from rats pretreated with HO-2 S-ODN. Hypoxia also was found to elicit slight contraction of vessels taken from rats pretreated with HO-1 AS-ODN but not with HO-1 S-ODN. Previous reports (14) showed that mild precontraction of isolated rat pulmonary arteries with an agonist such as PGF 2␣ enables these vessels to respond to acute hypoxia with a further contraction. In our study, before hypoxia, the basal isometric tension of untreated pulmonary vessels and of vessels taken from rats pretreated with HO-2 S-ODN tended to be exceeded (not significantly) by that of vessels pretreated with CrMP and vessels taken from rats pretreated with HO-2 AS-ODN. Conceivably, such borderline increments of basal tension may contribute to the enabling effect of pretreatment with CrMP or HO-2 AS-ODN on hypoxia-induced contraction of rat pulmonary arteries. However, this may not be the case because we found that pretreatment with CrMP intensifies hypoxia-induced contraction of pulmonary arterial vessels already precontracted with PGF 2␣ . Our finding that interventions, which decrease the activity or the expression of HO isoforms, have an enabling or intensifying influence on hypoxia-induced contraction of rat pulmonary arteries that may be taken to indicate that one or more HO products interfere with the mechanism(s) underlying the effect of hypoxia on pulmonary vascular tone. A similar conclusion was inferred from observations that interventions that induce pulmonary HO-1 prevent the increase in pulmonary arterial pressure observed in rats exposed to normobaric hypoxia for 1 wk (4).
The second key finding of our study, in rat pulmonary intralobar arteries treated with CrMP, is that the contractile response to acute hypoxia is attenuated by the inclusion of exogenous CO but not of biliverdin into the bathing buffer. Exogenous CO also was reported to inhibit hypoxic vasoconstriction in an in situ, blood-perfused, lung preparation (26) . Hence, CO is the product of pulmonary vascular HO activity most likely to interfere with the mechanism underlying hypoxia-induced contraction of pulmonary arterial vessels. Basal levels of CO production may be sufficient to disrupt such a mechanism because acute hypoxia did not increase CO release from pulmonary arterial vessels.
In agreement with some previous studies (14, 16, 38) , we found that the contractile response to acute hypoxia is less intense in pulmonary intralobar arteries denuded of endothelium than in arteries with intact endothelium. Such an observation suggests participation of an endothelium-derived constrictor factor in the implementation of hypoxia-induced pulmonary vasoconstriction. Pulmonary vascular endothelial cells produce ET-1 (31), which elicits pulmonary vasoconstriction acting on ET A and ET B receptors (8) . Participation of ET-1 in the pulmonary vasoconstrictor response to hypoxia is suggested by reports that pharmacological blockade of ET-1 receptors prevents hypoxia-induced pulmonary hypertension (23) . However, reports (9, 16) that ET-1 antagonists inhibit contractile responses to hypoxia in isolated pulmonary arterial vessels conflict with reports that they do not (13) . According to our study, in rat pulmonary intralobar arteries treated with CrMP, the ET A and ET B receptor blocker L-754142 attenuates the contractile response to hypoxia. Hence, during conditions of HO inhibition, hypoxia-induced contraction of pulmonary arterial vessels relies, at least in part, on a mechanism involving ET-1.
The third key finding of our study is that interventions that inhibit HO activity or HO-2 expression promote elevation of ET-1 levels in pulmonary intralobar arteries. Moreover, we also found that HO inhibition sensitizes the vascular smooth muscle to the contracting action of ET-1. That treatment with HO-2 AS-ODN or with CrMP increases ET-1 levels in pulmonary arterial vessels, particularly during hypoxic conditions, is in line with a report (18) that inhibition of HO augments the production of ET-1 by human umbilical vein endothelial cells cocultured with vascular smooth muscle cells during hypoxic conditions. These observations suggest that a product of HO activity, presumably CO, inhibits endothelial cell synthesis of ET-1, an action that may counteract the stimulatory action of hypoxia on ET-1 production (11). That CrMP sensitizes pulmonary intralobar arteries to ET-1-induced contraction is attributable to reduction of vascular CO because the sensitizing effect could be offset by exogenous CO. Altogether, these observations suggest that CO manufactured by pulmonary arterial vessels is an inhibitory modulator of both the vascular formation and constrictor action of ET-1.
Previous studies (10, 30, 37) documented that endogenous CO reduces the sensitivity of systemic small arterial vessels to constrictor stimuli, an action that was attributed to activation of large conductance K Ca channels in vascular smooth muscle. On the other hand, in the pulmonary circulation of rats, activation of soluble guanylyl cyclase rather than of K Ca channels is Fig. 9 . Mean pulmonary artery pressure in rats breathing air or a hypoxic gas mixture (5% O2-5% CO2-90% N2) for consecutive 2-min periods. The effect of hypoxia was examined in the absence of pretreatment with drugs, after pretreatment with CrMP (40 mol/kg iv), and after pretreatment with both CrMP and the nonselective ET-1 receptor antagonist L-745142 (15 mg/kg iv). Results are the means Ϯ SE of experiments in 6 rats. *P Ͻ 0.05, relative to data obtained during the air breathing period; †P Ͻ 0.05, relative to hypoxiainduced pressure change in the absence of drug pretreatment.
involved in the vasodilatory effect of exogenous CO (21) . Whether or not the inhibitory influence of HO-derived CO on the responsiveness of pulmonary intralobar arteries to ET-1 involves activation of K ϩ channels is unknown. The possibility merits consideration in view of observations linking hypoxiainduced contraction of pulmonary vascular smooth muscle cells to a reduction in K ϩ currents, which may involve synergistic interactions with ET-1 (16, 25, 34) .
The regulatory influence of HO-derived CO on hypoxiainduced pulmonary vasoconstriction is not limited to isolated vascular preparations. In this regard, our study in anesthetized rats documented that the elevation of pulmonary artery pressure caused by breathing a hypoxic gas mixture was intensified by pretreatment with CrMP to inhibit HO. That concurrent pretreatment with the ET-1 receptor antagonist L-745142 blunts the pulmonary pressor response to acute hypoxia in such animals suggests that endogenous CO minimizes the in vivo activity of an ET-1-dependent pulmonary pressor mechanism induced by acute hypoxic conditions. In summary, this study demonstrates that pulmonary arterial vessels express HO-1 and HO-2 and manufacture CO. HOderived CO interferes with the expression of hypoxia-induced pulmonary vasoconstriction both ex vivo and in vivo, in part by reducing vascular ET-1 levels and the sensitivity of the smooth muscle to the contracting action of the peptide. Hence, a heme-HO system intrinsic to the pulmonary vasculature modulates the constrictor response of pulmonary arterial vessels to acute hypoxia.
